Antibody used in the treatment of Bronchial Asthma is:
## **Core Concept**
The treatment of bronchial asthma involves various therapeutic approaches, including the use of monoclonal antibodies targeting specific pathways involved in the disease's pathophysiology. One key target in asthma treatment is the **interleukin-5 (IL-5) pathway**, which plays a crucial role in the growth and activation of eosinophils, a type of white blood cell involved in allergic reactions and asthma.
## **Why the Correct Answer is Right**
The correct answer, **Omalizumab**, is a monoclonal antibody used in the treatment of severe persistent allergic asthma. However, it specifically targets **IgE**, not IL-5. It works by binding to free IgE and membrane-bound IgE on B cells, preventing IgE from binding to the high-affinity IgE receptor (FcΞ΅RI) on mast cells and basophils. This action reduces the release of mediators involved in the allergic response.
However, for IL-5 targeted therapy:
- **Mepolizumab**, **Reslizumab**, and **Benralizumab** are examples of monoclonal antibodies that target IL-5 or its receptor. They are used for the treatment of severe asthma characterized by eosinophilic inflammation.
## **Why Each Wrong Option is Incorrect**
- **Option A:** Not provided, assuming it's an incorrect option related to asthma treatment.
- **Option B:** If another antibody not targeting the correct pathway for asthma treatment, it would be incorrect based on its mechanism of action not being relevant to asthma pathophysiology.
- **Option D:** Similarly, if another incorrect option, it would not align with current asthma treatment guidelines focusing on IgE or IL-5 pathways.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **Omalizumab** is specifically used for allergic asthma and targets **IgE**, while **Mepolizumab**, **Reslizumab**, and **Benralizumab** target the **IL-5 pathway**, useful in patients with eosinophilic asthma. These treatments represent a precision medicine approach, tailoring therapy to the individual patient's asthma phenotype.
## **Correct Answer:** . Omalizumab